Nivalis Therapeutics CEO Mitchell Gold's 2021 pay jumps 125% to $3.1M
Nivalis Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 29, 2022
Nivalis Therapeutics reported fiscal year 2021 executive compensation information on April 29, 2022.
In 2021, four executives at Nivalis Therapeutics received on average a compensation package of $2.2M, a 113% increase compared to previous year.
Average pay of disclosed executives at Nivalis Therapeutics
Mitchell H. Gold, Chief Executive Officer, received $3.1M in total, which increased by 125% compared to 2020. 74% of Gold's compensation, or $2.3M, was in option awards. Gold also received $301K in non-equity incentive plan and $523K in salary.
Stanford Peng, President and Head of Research and Development, received a compensation package of $2.5M, which increased by 149% compared to previous year. 55% of the compensation package, or $1.3M, was in option awards.
Zelanna Goldberg, Chief Medical Officer, earned $1.7M in 2021.
Paul Rickey, Chief Financial Officer, received $1.7M in 2021, which increases by 117% compared to 2020.
Related executives
You may also like
Source: SEC filing on April 29, 2022.